PATL2

Across TCGA pan-cancer cohorts, PATL2 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated PATL2 data layer compared with 25 for mass-spec protein.

The strongest signal is observed in mesothelioma (MESO), where higher PATL2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PATL2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

MESO, UCEC, and LIHC are the cancer types where PATL2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Median	All	0.130	0.557	.019	18	view →
UCEC	DFS	Median	II,III,IV	0.922	0.480	.030	6	view →
LIHC	OS	Median	All	0.286	0.690	.037	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

PATL2–MESO (OS)

Open the MESO breakdown →